Inotuzumab ozogamicin has achieved a markedly long antitumor response in patients with refractory or relapsed indolent B-cell non-Hodgkin lymphoma (NHL) in an ongoing phase II study. Interim findings were reported by lead investigator Kenneth Luu, PhD, associate director of Pfizer global R&D.
Leaders of the American Association for Cancer Research (AACR) have expressed deep concern that the ability of cancer researchers to bring the promise of science to improve outcomes for cancer patients in the United States is in peril due to a decade of declining budgets at the National Institutes of Health (NIH).
Hypofractionated stereotactic radiotherapy (SRT) appears to be safe and effective in preventing recurrence at resection cavities following surgical resection of brain metastasis and may spare many patients from whole brain radiotherapy (WBRT) and its adverse effects.
Development of a Novel Therapeutic Agent for Breast Cancer Based on a New Pathway Analysis of Triple-Negative Breast Cancer
Development of a novel method for drug discovery using active compounds as pharmacodynamic biomarkers in triple-negative breast cancer cell lines.
'Striking' Results Seen in Phase II Trial of Selumetinib in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum
Selumetinib, a small-molecule MEK inhibitor, controlled recurrent low-grade serous ovarian cancer in 81% of patients treated. Current first-line defense against this disease (surgery followed by cytotoxic chemotherapy) has met with limited success.
Addition of a Janus kinase 2 (JAK2) inhibitor to therapies that target commonly altered oncogenes such as KRAS or EGFR could improve clinical outcomes for patients with non–small cell-lung cancer.
Photoacoustic tomography (PAT), a new imaging technique that relies on light and sound, provides in vivo multiscale nonionizing functional and molecular imaging without the radiation emitted by x-rays and CT scans, explained Lihong V. Wang, PhD, who led the team of developers at Washington University in St. Louis.
Novel Approach of Phase I/II Trial Seeks Optimal Rather Than Maximum Tolerated Dose for Potent Epigenetic Drug Targeting Myelodysplastic Syndromes and Leukemia
Preliminary findings of a phase I/II randomized clinical trial indicate that SGI-110, a novel DNA methylation inhibitor, is safe, well tolerated and efficacious in patients with acute myelogenous leukemia.
Treatment with tremelimumab stabilized patients with advanced hepatocellular carcinoma due to chronic hepatitis C infection for more than 12 months, according to data from a phase II clinical trial presented at the AACR annual meeting.
A combination of TL32711, an investigational second mitochondrial-derived activator of caspases (Smac), and tumor necrosis factor-related apoptosis inducing ligand at low concentrations produced marked apoptosis in germinal center lines, with minimal to no effect for each agent alone.